AJOVY is indicated for the preventive treatment of migraine in adults.

You can also browse the topics below to find what you are looking for.

MORE MIGRAINE-FREE DAYS IN PATIENTS WITH AN INADEQUATE RESPONSE TO ≥2 PRIOR PREVENTIVE TREATMENTS1*

The FOCUS study demonstrated significant reduction in average monthly migraine days compared to placebo after inadequate response to 2 or more classes of preventive treatments (primary endpoint)1

See Study Design >

CHANGE FROM BASELINE IN AVERAGE MONTHLY MIGRAINE DAYS DURING THE FOCUS PHASE 3B STUDY1

Bar chart displaying primary endpoint data of the FOCUS study.

Improvements were seen as early as week 1 and were sustained throughout the 3-month treatment period (exploratory endpoint)2†

†For all exploratory analyses, no determination of statistical significance can be made and no conclusions should be drawn.

≥50% reduction in migraine days vs placebo

PERCENTAGE OF PATIENTS ACHIEVING ≥50% REDUCTION IN AVERAGE MONTHLY MIGRAINE DAYS VS PLACEBO DURING THE 12-WEEK STUDY PERIOD (SECONDARY ENDPOINT)1

Bar chart displaying secondary endpoint data of the FOCUS study.

34% of patients achieved a ≥50% reduction of average monthly migraine days with either monthly or quarterly dosing vs 9% for placebo (P<0.0001) (secondary endpoint)1

Results in patients with an inadequate response to anticonvulsants or neurotoxins (exploratory analysis)‡

  • 3.8 mean reduction from baseline in monthly average migraine days for both monthly and quarterly arms vs 1.0 for placebo in patients with previous anticonvulsant use2
  • 2.7 and 3.2 mean reduction from baseline in monthly average migraine days for both monthly and quarterly dosing arms, respectively, vs 0.2 for placebo in patients who previously used neurotoxins2

‡For all exploratory analyses, no determination of statistical significance can be made and no conclusions should be drawn.


Patients experienced a significant reduction in the monthly average number of days using migraine-specific acute headache medication (secondary endpoint)2

  • Mean reduction of 3.9 days for monthly dosing and 3.7 days for quarterly dosing of migraine-specific acute headache medication use vs 0.6 days with placebo2
NOW is the time for AJOVY
​

*Inadequate response to a prior medication was defined as: (1) no clinically meaningful improvement after at least 3 months (2) patient could not tolerate the drug (3) drug was contraindicated for patient or (4) drug was not suitable for the patient.1

References: 1. Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet.
2019;394(10203):1030-1040. 2. Data on file. Parsippany, NJ: Teva Pharmaceuticals USA, Inc.